MA54615A - Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation - Google Patents
Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisationInfo
- Publication number
- MA54615A MA54615A MA054615A MA54615A MA54615A MA 54615 A MA54615 A MA 54615A MA 054615 A MA054615 A MA 054615A MA 54615 A MA54615 A MA 54615A MA 54615 A MA54615 A MA 54615A
- Authority
- MA
- Morocco
- Prior art keywords
- monoclonal antibody
- antibody against
- against human
- human interleukin
- alpha receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811592427.XA CN110746507B (zh) | 2018-12-25 | 2018-12-25 | 抗人白介素4受体α单克隆抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54615A true MA54615A (fr) | 2021-11-03 |
Family
ID=69275667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054615A MA54615A (fr) | 2018-12-25 | 2019-12-25 | Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220073631A1 (fr) |
EP (1) | EP3902837A4 (fr) |
JP (1) | JP7118480B2 (fr) |
CN (5) | CN111494625B (fr) |
AU (1) | AU2019416486B2 (fr) |
CA (1) | CA3124726A1 (fr) |
MA (1) | MA54615A (fr) |
WO (1) | WO2020135471A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494625B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
CN113527485A (zh) * | 2020-04-17 | 2021-10-22 | 上海麦济生物技术有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
CN113549151A (zh) * | 2020-04-24 | 2021-10-26 | 苏州康乃德生物医药有限公司 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
CN114605539B (zh) * | 2020-12-09 | 2024-01-02 | 南京融捷康生物科技有限公司 | 人源化的抗IL-4Rα单域抗体及其应用 |
EP4019546A1 (fr) * | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Domaines variables d'anticorps qui se lient à il-31 |
EP4019090A1 (fr) * | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Domaines variables d'anticorps liant il-4r |
EP4267615A1 (fr) * | 2020-12-23 | 2023-11-01 | Numab Therapeutics AG | Domaines variables d'anticorps se liant à il-4r |
EP4019547A1 (fr) * | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Anticorps multispécifiques ayant une spécificité pour il-4r et il-31 |
TW202328183A (zh) | 2021-08-05 | 2023-07-16 | 美商美國禮來大藥廠 | 人類介白素-4受體α抗體 |
US20240024472A1 (en) | 2022-05-02 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations |
US20240199688A1 (en) | 2022-05-02 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
CN115960236A (zh) * | 2023-01-05 | 2023-04-14 | 江苏荃信生物医药股份有限公司 | 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (fr) * | 1992-12-29 | 1994-07-06 | Schering-Plough | Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
AU2001272925A1 (en) | 2000-05-26 | 2001-12-11 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
MXPA06004853A (es) | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
BRPI0710572A2 (pt) | 2006-01-24 | 2013-01-08 | Domantis Ltd | ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
MY149079A (en) * | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
US20100008914A1 (en) | 2006-12-15 | 2010-01-14 | Murray Lynne A | Methods and compositions for treating il-4 and il-13 related fibrosis related pathologies |
EP2050764A1 (fr) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
EP3211010A1 (fr) | 2007-12-21 | 2017-08-30 | Medimmune Limited | Éléments de liaison pour le récepteur alpha interleukin-4 (il-4r) - 173 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
WO2009114828A1 (fr) | 2008-03-13 | 2009-09-17 | Childrens Hospital Medical Center | Compositions et procédés relatifs à des états d’allergie gastro-intestinale |
JP6161233B2 (ja) | 2008-03-31 | 2017-07-12 | ジェネンテック, インコーポレイテッド | 喘息の治療及び診断のための組成物及び方法 |
US20110008326A1 (en) * | 2008-04-02 | 2011-01-13 | Oliver Hill | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
WO2010054667A1 (fr) * | 2008-11-17 | 2010-05-20 | Københavns Universitet | Peptides dérivés d’il-4 pour la modulation de la réponse inflammatoire chronique et le traitement de maladies auto-immunes |
TR201901826T4 (tr) * | 2011-12-13 | 2019-03-21 | Astrazeneca Ab | Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler. |
WO2013087912A1 (fr) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Composés et méthodes de traitement de maladies inflammatoires |
HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
KR102576903B1 (ko) * | 2012-09-07 | 2023-09-13 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제 투여로 아토피성 피부염을 치료하는 방법 |
SG10201913822PA (en) * | 2012-09-07 | 2020-03-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
KR20150139905A (ko) | 2013-04-05 | 2015-12-14 | 제넨테크, 인크. | 항-il-4 항체 및 이중특이적 항체 및 그의 용도 |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
CN105517570B (zh) | 2013-06-21 | 2020-04-07 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
MX2016010854A (es) | 2014-02-21 | 2017-01-05 | Sanofi Biotechnology | Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r. |
ES2973858T3 (es) | 2014-02-28 | 2024-06-24 | Regeneron Pharma | Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R |
US20170281769A1 (en) * | 2014-09-03 | 2017-10-05 | Medimmune Limited | STABLE ANTI-IL-4Ra FORMULATION |
CN107206073A (zh) | 2014-11-14 | 2017-09-26 | 赛诺菲生物技术公司 | 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法 |
CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
CA3035202A1 (fr) | 2016-09-01 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Methodes de prevention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
KR20190053250A (ko) * | 2016-09-22 | 2019-05-17 | 리제너론 파아마슈티컬스, 인크. | Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법 |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
CN108409860B (zh) * | 2017-02-10 | 2021-10-15 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
CN108640991B (zh) * | 2018-05-17 | 2019-09-27 | 江苏荃信生物医药有限公司 | 抗人白介素17a单克隆抗体及其应用 |
CN111494625B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
-
2018
- 2018-12-25 CN CN202010424479.7A patent/CN111494625B/zh active Active
- 2018-12-25 CN CN202010424500.3A patent/CN111518211B/zh active Active
- 2018-12-25 CN CN201811592427.XA patent/CN110746507B/zh active Active
- 2018-12-25 CN CN202010424497.5A patent/CN111494626B/zh active Active
- 2018-12-25 CN CN202010425210.0A patent/CN111514292B/zh active Active
-
2019
- 2019-12-25 MA MA054615A patent/MA54615A/fr unknown
- 2019-12-25 JP JP2021537939A patent/JP7118480B2/ja active Active
- 2019-12-25 EP EP19902812.7A patent/EP3902837A4/fr active Pending
- 2019-12-25 CA CA3124726A patent/CA3124726A1/fr active Pending
- 2019-12-25 US US17/418,571 patent/US20220073631A1/en active Pending
- 2019-12-25 WO PCT/CN2019/128156 patent/WO2020135471A1/fr unknown
- 2019-12-25 AU AU2019416486A patent/AU2019416486B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN111494625A (zh) | 2020-08-07 |
CN110746507B (zh) | 2020-06-26 |
WO2020135471A1 (fr) | 2020-07-02 |
US20220073631A1 (en) | 2022-03-10 |
CN111494626A (zh) | 2020-08-07 |
AU2019416486B2 (en) | 2022-07-07 |
JP7118480B2 (ja) | 2022-08-16 |
EP3902837A1 (fr) | 2021-11-03 |
JP2022516483A (ja) | 2022-02-28 |
CN111494626B (zh) | 2022-06-21 |
CN111494625B (zh) | 2022-06-21 |
AU2019416486A1 (en) | 2021-07-08 |
CN111518211A (zh) | 2020-08-11 |
CN111514292B (zh) | 2023-06-20 |
CN110746507A (zh) | 2020-02-04 |
CN111518211B (zh) | 2022-06-21 |
CN111514292A (zh) | 2020-08-11 |
CA3124726A1 (fr) | 2020-07-02 |
EP3902837A4 (fr) | 2022-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54615A (fr) | Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation | |
MA52091A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
IL284216B (en) | Anti-transferrin receptor antibodies and their uses | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
EP3878868A4 (fr) | Anticorps humain présentant une affinité élevée vis-à-vis du récepteur alpha d'il -4 humain, et son utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA52284A (fr) | Anticorps anti-hla-g et leur utilisation | |
MA49512A (fr) | Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation | |
MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
MA50038A (fr) | Anticorps anti-pd-l1 de et son utilisation | |
MA52285A (fr) | Anticorps multispécifiques et leur utilisation | |
MA54089A (fr) | Anticorps anti-pd-1 humain et procédés d'utilisation associés | |
MA50534A (fr) | Variant d'anticorps et isoforme à activité biologique réduite | |
EA202191806A1 (ru) | Антитело против человеческого il-4ra и его применение | |
MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation | |
MA55615A (fr) | Anticorps humains qui se lient au ret et leurs procédés d'utilisation | |
MA52014A (fr) | Anticorps anti-klk5 et méthodes d'utilisation | |
EP4169948A4 (fr) | Anticorps anti-cd73 et son utilisation | |
MA51902A (fr) | Schémas posologiques d'anticorps b7-h4 | |
IL287690A (en) | Antibodies against hvem and their use | |
MA52165A (fr) | Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée | |
ZA202104518B (en) | Cd3 antibody and pharmaceutical use thereof |